American Society of Hirudotherapy

Revisiting the Efficacy and Safety of Bivalirudin in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From a Mixed Treatment Comparison Meta-Analysis of Randomized Trials

Mixed treatment comparison meta-analysis of randomized trials published in Catheterization and Cardiovascular Interventions (2024)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Meta-analysisClinical LiteratureDrug DevelopmentMaqsood MH et al. · Catheterization and cardiovascular interventions, 2025

Abstract

BACKGROUND: Randomized trials of bivalirudin in patients with ST elevation myocardial infarction (STEMI) have yielded heterogeneous results. AIMS: Our aim was to evaluate the efficacy and safety of four antithrombin regimens-unfractionated heparin (UFH), bivalirudin (stopped soon after percutaneous coronary intervention [PCI]), extended bivalirudin (continued for a few hours after PCI), and combined UFH and a Gp2b3a inhibitors (GPI) in patients who present with STEMI. METHODS: A PubMed, EMBASE, and clinicaltrials.gov databases were searched for randomized clinical trials (RCTs) of the above antithrombin in patients with STEMI. The primary outcome was net adverse cardiovascular events (NACE). The primary ischemic endpoint was major adverse cardiovascular events (MACE), and the primary safety endpoint was major bleeding, and other endpoints included all-cause mortality and stent thrombosis. The primary analysis compared the effect of these antithrombin regimens in reference to UFH using a mixed treatment comparison meta-analysis. RESULTS: In the 14 RCTs evaluating 25,415 patients with STEMI, when compared to UFH monotherapy, extended bivalirudin lowered NACE (OR = 0.71 with 95% CI: 0.53-0.96; moderate level of confidence) driven by a significant decrease in major bleeding (OR = 0.42 with 95% CI: 0.26-0.68; high level of confidence) without any significant difference in MACE or all-cause mortality. When compared with UFH monotherapy, UFH+GPI reduced risk of MACE (OR = 0.76 with 95% CI: 0.60-0.97; high level of confidence) but at the expense of an increase in major bleeding (OR = 1.48 with 95% CI: 1.11-1.98; high level of confidence) with no difference in NACE or all-cause mortality. For major bleeding, extended bivalirudin infusion ranked #1, bivalirudin ranked #2, UFH monotherapy ranked #3, and combined UFH and GPI ranked #4. For NACE, extended bivalirudin infusion ranked #1, bivalirudin ranked #2, combined UFH and GPI ranked #3, and UFH monotherapy ranked #4. Cluster plots for MACE and major bleeding demonstrated that extended bivalirudin had the best balance for efficacy and safety. CONCLUSIONS: In patients undergoing PCI for STEMI, extended bivalirudin offers the best balance for primary ischemic (MACE) and safety (major bleeding) outcomes.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeMeta-AnalysisJournal ArticleSystematic Review
Indexed MeSH termsHirudinsHumansST Elevation Myocardial InfarctionPercutaneous Coronary InterventionRecombinant ProteinsPeptide FragmentsRandomized Controlled Trials as TopicAntithrombinsTreatment OutcomeHemorrhageRisk FactorsHeparinTime FactorsDrug Therapy, CombinationDrug Administration ScheduleMaleCoronary ThrombosisRisk AssessmentFemaleMiddle AgedAgedPlatelet Aggregation Inhibitors

Summary

Mixed-treatment-comparison meta-analysis of 14 trials (25,415 STEMI patients) found extended bivalirudin lowered net adverse cardiovascular events versus heparin, driven by reduced major bleeding, with no significant mortality difference and the best efficacy-safety balance.

Why This Matters for Hirudotherapy

This systematic review and meta-analysis evaluated four antithrombin regimens—including bivalirudin—versus unfractionated heparin in 25,415 STEMI patients across 14 RCTs undergoing percutaneous coronary intervention. Extended bivalirudin infusion ranked first for both net adverse cardiovascular events and major bleeding reduction, suggesting the best efficacy-safety balance among the regimens studied. The findings are specific to pharmaceutical anticoagulation in interventional cardiology. Bivalirudin (formerly Hirulog) is a synthetic peptide anticoagulant designed partly on the C-terminal sequence of hirudin, the anticoagulant of the medicinal leech (Maraganore et al., 1990); this paper studies the drug, not leech therapy.

Citation

Reference (Vancouver style)

Maqsood MH, Tamis-Holland JE, Feit F, Bangalore S. Revisiting the Efficacy and Safety of Bivalirudin in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From a Mixed Treatment Comparison Meta-Analysis of Randomized Trials. Catheter Cardiovasc Interv. 2025;105(1):54-67. doi:10.1002/ccd.31276. PMID: 39506500

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.